439 related articles for article (PubMed ID: 19010832)
1. Microtubule active agents: beyond the taxane frontier.
Morris PG; Fornier MN
Clin Cancer Res; 2008 Nov; 14(22):7167-72. PubMed ID: 19010832
[TBL] [Abstract][Full Text] [Related]
2. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G
Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795
[TBL] [Abstract][Full Text] [Related]
3. Tubulin and microtubules as targets for anticancer drugs.
Hadfield JA; Ducki S; Hirst N; McGown AT
Prog Cell Cycle Res; 2003; 5():309-25. PubMed ID: 14593726
[TBL] [Abstract][Full Text] [Related]
4. Ixabepilone and other epothilones: microtubule-targeting agents for metastatic breast cancer.
Morris PG; Fornier MN
Clin Adv Hematol Oncol; 2009 Feb; 7(2):115-22. PubMed ID: 19367253
[TBL] [Abstract][Full Text] [Related]
5. Update on tubulin-binding agents.
Attard G; Greystoke A; Kaye S; De Bono J
Pathol Biol (Paris); 2006 Mar; 54(2):72-84. PubMed ID: 16545633
[TBL] [Abstract][Full Text] [Related]
6. Microtubules: a dynamic target in cancer therapy.
Pasquier E; Kavallaris M
IUBMB Life; 2008 Mar; 60(3):165-70. PubMed ID: 18380008
[TBL] [Abstract][Full Text] [Related]
7. Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance.
Perez EA
Mol Cancer Ther; 2009 Aug; 8(8):2086-95. PubMed ID: 19671735
[TBL] [Abstract][Full Text] [Related]
8. Probing the pore drug binding site of microtubules with fluorescent taxanes: evidence of two binding poses.
Barasoain I; García-Carril AM; Matesanz R; Maccari G; Trigili C; Mori M; Shi JZ; Fang WS; Andreu JM; Botta M; Díaz JF
Chem Biol; 2010 Mar; 17(3):243-53. PubMed ID: 20338516
[TBL] [Abstract][Full Text] [Related]
9. Cevipabulin (TTI-237): preclinical and clinical results for a novel antimicrotubule agent.
Ayral-Kaloustian S; Zhang N; Beyer C
Methods Find Exp Clin Pharmacol; 2009 Sep; 31(7):443-7. PubMed ID: 19907719
[TBL] [Abstract][Full Text] [Related]
10. Development of other microtubule-stabilizer families: the epothilones and their derivatives.
Brogdon CF; Lee FY; Canetta RM
Anticancer Drugs; 2014 May; 25(5):599-609. PubMed ID: 24398663
[TBL] [Abstract][Full Text] [Related]
11. Targeting the microtubules in breast cancer beyond taxanes: the epothilones.
Cortes J; Baselga J
Oncologist; 2007 Mar; 12(3):271-80. PubMed ID: 17405891
[TBL] [Abstract][Full Text] [Related]
12. Epothilones: mechanism of action and biologic activity.
Goodin S; Kane MP; Rubin EH
J Clin Oncol; 2004 May; 22(10):2015-25. PubMed ID: 15143095
[TBL] [Abstract][Full Text] [Related]
13. Novel agents that target tublin and related elements.
Rowinsky EK; Calvo E
Semin Oncol; 2006 Aug; 33(4):421-35. PubMed ID: 16890797
[TBL] [Abstract][Full Text] [Related]
14. Current perspectives of epothilones in breast cancer.
Cardoso F; de Azambuja E; Lago LD
Eur J Cancer; 2008 Feb; 44(3):341-52. PubMed ID: 18178426
[TBL] [Abstract][Full Text] [Related]
15. Microtubule alterations and resistance to tubulin-binding agents (review).
Drukman S; Kavallaris M
Int J Oncol; 2002 Sep; 21(3):621-8. PubMed ID: 12168109
[TBL] [Abstract][Full Text] [Related]
16. Tubulin: an example of targeted chemotherapy.
Seligmann J; Twelves C
Future Med Chem; 2013 Mar; 5(3):339-52. PubMed ID: 23464522
[TBL] [Abstract][Full Text] [Related]
17. Exploring the mechanisms of action of the novel microtubule inhibitor vinflunine.
Jordan MA; Horwitz SB; Lobert S; Correia JJ
Semin Oncol; 2008 Jun; 35(3 Suppl 3):S6-S12. PubMed ID: 18538179
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents.
Fojo T; Menefee M
Ann Oncol; 2007 Jul; 18 Suppl 5():v3-8. PubMed ID: 17656560
[TBL] [Abstract][Full Text] [Related]
19. The epothilones: how pharmacology relates to clinical utility.
Michaud LB
Ann Pharmacother; 2009 Jul; 43(7):1294-309. PubMed ID: 19584389
[TBL] [Abstract][Full Text] [Related]
20. Microtubule stabilising agents for cancer chemotherapy.
Zhao Y; Fang WS; Pors K
Expert Opin Ther Pat; 2009 May; 19(5):607-22. PubMed ID: 19441937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]